Adagene Inc.
ADAGHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeAdagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. The $161.8M market capitalization puts ADAG squarely in micro-cap range for its industry. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.
Market Cap
$161.8M
Beta
0.54
P/E (TTM)
—
P/E (Fwd)
-4.30
EPS (TTM)
$-0.38
EPS (Fwd)
$-0.56
ROE
-28.5%
ROA
-14.0%
Cash
$127.9M
Total Debt
$6.1M
Free CF
-$12.2M
52W Change
30.6%
Annual Financials
Cash vs Debt
Where ADAG stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ADAG finished 36.74% below its 150-day moving average ($3.62) and 32.45% below its 200-day moving average ($3.39). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ADAG overbought or oversold?
At the October 20, 2026 close, ADAG's RSI(14) was 25.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Adagene Inc. holds $127.9M in cash against $6.1M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$12.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -28.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $9.3M to $7.7M.
ADAG's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Adagene Inc.'s trajectory.